secwatch.observer — SEC 8-K summary
======================================

Issuer:     BriaCell Therapeutics Corp. (BCTX)
CIK:        0001610820
Form:       8-K
Filed at:   2023-09-08T23:59:59+00:00
Accession:  0001493152-23-032041
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BriaCell Phase 2 breast cancer study shows 13.5-month median overall survival vs 6.7-9.8 months literature
--------------------------------------------------------------------------------

- Median overall survival 13.5 months in BriaCell's Phase 2 study vs 6.7-9.8 months for similar advanced metastatic breast cancer patients in literature.
- 21 of 29 patients treated since 2022 remain alive, suggesting strong survival benefit with combination regimen.
- No dose limiting toxicities reported; Phase 2 study fully enrolled with 46 heavily pre-treated patients (average 5 prior treatments).
- Combination regimen of Bria-IMT™ with checkpoint inhibitors (pembrolizumab or retifanlimab-dlwr) shows tolerability and efficacy.
- Data supports upcoming pivotal study in advanced breast cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610820/000149315223032041/0001493152-23-032041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610820/000149315223032041/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-032041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer